Aptevo Therapeutics (APVO) SVP, CSO files Form 3 reporting zero shares

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. executive Mary Jo Janatpour, SVP and Chief Scientific Officer, filed an initial Form 3 reporting her beneficial ownership of the company’s Common Stock. The filing shows she held 0 shares of Common Stock directly following the reporting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Janatpour Mary Jo

Role SVP, CSO

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Direct, null)

Footnotes (1)

Key Figures

Common Stock held: 0 shares

1 metrics

Common Stock held 0 shares Total shares beneficially owned following reporting date

Key Terms

Form 3, Common Stock, beneficial ownership

3 terms

Form 3 regulatory

"filed an initial Form 3 reporting her beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Common Stock financial

"0 shares of Common Stock directly following the reporting date"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

beneficial ownership financial

"filed an initial Form 3 reporting her beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Janatpour Mary Jo

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WASHINGTON 98121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/20/2026

3. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CSO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ SoYoung Kwon, Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Mary Jo Janatpour’s Form 3 for APVO disclose?

The Form 3 for Aptevo Therapeutics (APVO) shows that SVP and CSO Mary Jo Janatpour reported 0 shares of Common Stock beneficially owned. This is an initial ownership statement required when becoming a reporting insider.

Does the APVO Form 3 show any insider buying or selling?

No insider buying or selling is shown in this APVO Form 3. It is an initial beneficial ownership report, and the position reported is 0 shares of Common Stock, with no transaction amounts or prices disclosed.

What role does the reporting person hold at Aptevo Therapeutics (APVO)?

The reporting person, Mary Jo Janatpour, is identified as an officer of Aptevo Therapeutics with the title SVP, CSO. This officer status triggers ongoing reporting obligations for her holdings in the company’s Common Stock.

Why is Aptevo Therapeutics’ Form 3 filing important for APVO investors?

Form 3 filings give investors a baseline of an insider’s initial ownership. For APVO, this filing shows the SVP and CSO starting with 0 shares, helping investors track any future changes in her Common Stock position through subsequent Forms 4 or 5.

What type of security is reported in this APVO Form 3?

The Form 3 reports Common Stock of Aptevo Therapeutics Inc. as the relevant security class. The total reported beneficial ownership following the reporting date is 0 shares, with direct ownership listed and no derivative securities disclosed.